Source Articles
Pazopanib
Showing 3 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62 | 18 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | Multi-target TKI | Pazopanib | — | Missing | extra-cranial | other | Extremities | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Gebbia et al. | 2020 | Retrospective | Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World | 10.21873/anticanres.14730 | — | 28 | 64 | Missing | Kidney cancer | oligometastatic, metastatic | Multi-target TKI | Pazopanib | — | Missing | both | brain, lung, liver, bone, LN unspecified, other | kidney, skin | Missing | 21.0 | 50.0 | Missing | Missing | Missing | Missing | Missing | Missing | Treatment-rel. | — | — | 7 | any G3-4: 7 AEs | any G3-4: unknown pts |
any G3-4: Hypertension, diarrhea, anemia, liver, pneumonitis
|
unknown
|
| De Wolf et al. | 2017 | Prospective | Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial | 10.1186/s13014-017-0893-x | NCT02334709 | 13 | 66 | Missing | Kidney cancer | metastatic | Multi-target TKI | Pazopanib | — | 13 | extra-cranial | lung, liver, bone, LN unspecified, other | soft tissue, pancreas | 30 | 24.0 | 36.0 | 3 | 3 | 3 | 10 | 8 | 12 | Treatment-rel. | — | — | 5 | any G3-4: 6 AEs | any G3-4: 5 pts |
any G3-4: hypoglycemie, increased ALT and increased AST, hypertension
|
/
|